Soluble adenylyl cyclase defines a nuclear cAMP microdomain in keratinocyte hyperproliferative skin diseases.

TitleSoluble adenylyl cyclase defines a nuclear cAMP microdomain in keratinocyte hyperproliferative skin diseases.
Publication TypeJournal Article
Year of Publication2010
AuthorsZippin JH, Chadwick PA, Levin LR, Buck J, Magro CM
JournalJ Invest Dermatol
Volume130
Issue5
Pagination1279-87
Date Published2010 May
ISSN1523-1747
KeywordsAdenylyl Cyclases, Animals, Caco-2 Cells, Cell Differentiation, Cell Nucleus, Cyclic AMP, Dogs, Epidermis, Humans, Keratinocytes, Keratosis, Kidney, Membrane Microdomains, Molluscum Contagiosum, Psoriasis, Signal Transduction, Skin Diseases, Skin Neoplasms, Solubility, Transcription, Genetic, Ultraviolet Rays
Abstract

Cyclic adenosine monophosphate (cAMP) is a nearly ubiquitous signaling molecule important for numerous signaling pathways in human skin. We studied a novel class of mammalian adenylyl cyclase, the soluble adenylyl cyclase (sAC). We examined sAC localization in normal human skin and found it to be present in keratinocytes, melanocytes, mononuclear cells, eccrine ducts, and nerves. In normal skin, sAC keratinocyte staining was evenly distributed throughout the cell. However, in certain hyperproliferative disorders of the skin, including psoriasis, verruca vulgaris, and SCCIS on sun-damaged skin, sAC keratinocyte staining was predominantly nuclear. In contrast, in other hyperproliferative disorders, such as basal cell carcinoma, sAC staining was similar to normal human skin. Using a model of epithelial differentiation, we established that sAC migrates into the nucleus when differentiated cells are induced to reenter the cell cycle. Previous work had determined that nuclear sAC activates the cAMP-response-element-binding (CREB) transcription factor, and we found that in psoriasis lesions, nuclear sAC occurs concomitantly with activation of CREB. Hence, sAC may play a role in the pathogenesis of certain hyperproliferative skin disorders via modulation of gene expression.

DOI10.1038/jid.2009.440
Alternate JournalJ. Invest. Dermatol.
PubMed ID20130594
PubMed Central IDPMC3082439
Grant ListNS55255 / NS / NINDS NIH HHS / United States
R01 GM062328-08 / GM / NIGMS NIH HHS / United States
R01 GM062328 / GM / NIGMS NIH HHS / United States
R01 NS055255 / NS / NINDS NIH HHS / United States
R01 HD059913 / HD / NICHD NIH HHS / United States
HD059913 / HD / NICHD NIH HHS / United States
R01 GM062328-07 / GM / NIGMS NIH HHS / United States
GM62328 / GM / NIGMS NIH HHS / United States